# PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

Source: https://onco.cc/trials/nct07477418/  
OnCo record `nct07477418` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by University of Vermont, not yet recruiting.

## Summary

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) is a phase 1/2, interventional study registered as NCT07477418 by University of Vermont, with a registry enrolment figure of 10 participants, started 2026-12 and due to reach its primary completion in 2030-12. Interventions recorded: Gemcitabine Delivered by Transarterial Microperfusion. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC); Borderline Resectable Pancreatic Cancer; Pancreatic Neoplasms. Primary outcome: Safety and Tolerability of Neoadjuvant Transarterial Gemcitabine Delivery. Pancreatic eligibility wording from the registry: "* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: PRISM-TAMP
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07477418
- Phase: 1/2
- Setting: PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP): A Phase Ib/II Open-Label Trial
- Sponsor: University of Vermont
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT07477418: https://clinicaltrials.gov/study/NCT07477418

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07477418.json